CAMBRIDGE, Mass.– Aurion Biotech, a clinical-stage regenerative medicine company focused on vision restoration, has announced two key leadership appointments aimed at accelerating the development of its experimental cell therapy for corneal endothelial disease. Edward J. Holland, M.D., has been named Chief Medical Officer, while Eris P. Jordan, O.D., a company co-founder, has been appointed Chief Development Officer.
The company is currently advancing AURN001, a single-dose allogeneic cell therapy designed to treat corneal edema caused by corneal endothelial disease — a degenerative condition affecting millions globally and leading to progressive vision loss.
Dr. Holland, a globally recognized expert in corneal disease, has been involved with Aurion since its inception. As Chair of the Medical Advisory Board, he led the first U.S. team to administer the therapy, developed from technology pioneered by Professor Shigeru Kinoshita of Kyoto Prefecture University of Medicine. His appointment is seen as a critical move as Aurion prepares for late-stage clinical trials.
“His dedication to patients and leadership in corneal care have been instrumental to the success of our program,” said Aurion CEO Arnaud Lacoste, Ph.D., M.B.A. “His appointment as Chief Medical Officer further strengthens our clinical and scientific foundation.”
Dr. Jordan has been integral to the company’s clinical strategy from the beginning. She led early-stage trials in El Salvador — including the IOTA and ESCALON studies — and has expanded the company’s clinical development into North America. Her elevation to Chief Development Officer reflects her ongoing commitment to both patients and the corneal care community.
“Her leadership of our global clinical trials has been extraordinary,” Lacoste said. “I’m honored to continue working with Eris as Chief Development Officer.”
Both leaders emphasized their focus on delivering meaningful treatment options for patients with limited access to effective therapies.
“I’ve seen firsthand the transformative potential of AURN001,” Dr. Holland said. “It’s exciting to officially join the team and help drive this therapy toward broader patient access.”
“This program has always been about the patients — those we’ve already helped and those still waiting,” said Dr. Jordan. “I’m proud to help lead this next phase of development alongside a team so committed to scientific excellence and care.”
Aurion Biotech’s leadership reshuffle is expected to enhance its efforts to bring AURN001 to market and fulfill its mission of restoring vision on a global scale.
